August 19, 2014

The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.

August 11, 2014

Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million. 

June 30, 2014

Afrezza, an inhaled insulin powder meant to treat diabetes patients, was approved Friday by the Food and Drug Administration.

June 19, 2014

Novo Nordisk on Thursday announced the launch of Levemir FlexTouch (insulin detemir [rDNA origin] injection), a prefilled insulin delivery mechanism, providing a new way for diabetics to administer their insulin.

June 12, 2014

A study published Wednesday on JAMA's website found that diabetes patients taking metformin had a higher risk of all-cause death when insulin was added to their treatment as compared to when sulfonylureas were added to treatment.

May 19, 2014

New research published in Diabetologia, the journal of the European Association for the Study of Diabetes, found that brief bursts of intense exercise before meals — termed exercise "snacking" by the study authors — helps control blood sugar in people with insulin resistance more effectively than one daily 30-minute session of moderate exercise.

April 3, 2014

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

February 28, 2014

Pharma Supply earlier this week launched NeedleBay, a safe and easy method of organizing and dispensing insulin pen needles and medication.

January 21, 2014

Novo Nordisk has launched a new insulin pen designed for children with diabetes.

November 1, 2013

The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

August 28, 2013

Swiss Precision Diagnostics recently launched its Clearblue Advanced Pregnancy Test with Weeks Estimator — the first and only pregnancy test that also provides an estimate of time since ovulation for women testing pregnant — into the U.S. marketplace.

August 21, 2013

The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

August 2, 2013

Novo Nordisk is offering $80,000 to diabetes-education programs in a Minnesota city, the Danish drug maker said Friday.

April 9, 2013

The developer of an amino acid compound is issuing a new license for the product.

April 5, 2013

Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said.

March 25, 2013

SanMedica International introduced its SeroVital-HGH, a new oral human-growth hormone booster formulated with women in mind, at the Academy of Women's Health's Annual Congress.

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

February 11, 2013

The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

December 27, 2012

Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC.

December 6, 2012

The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

November 28, 2012

Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

November 9, 2012

A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

September 21, 2012

The National Advertising Division on Thursday recommended that Church & Dwight discontinue its claim that the company’s First Response digital ovulation test is the “first and only test to predict ovulation based on your unique LH hormone level.”

June 12, 2012

One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.